Key Takeaways
- Xenon filed an NDA for azetukalner as a focal seizures treatment, potentially its first marketed product
- New enrollment halted in depression and bipolar trials following neuropsychiatric safety concerns
- Shares plunged 25% to $42.84 during premarket hours on Friday
- Analyst opinions diverged: Deutsche Bank downgraded to Hold at $46, while Wells Fargo maintained Overweight
- Needham reduced target to $60 from $78 while keeping Buy rating, eliminating psychiatric indication revenue forecasts
Xenon Pharmaceuticals submitted a New Drug Application for azetukalner targeting focal seizures on Thursday, representing a crucial milestone toward launching its inaugural commercial therapy. However, this achievement was immediately eclipsed by troubling clinical news.
Simultaneously with the NDA filing, Xenon revealed it had suspended enrollment of new participants in its depression and bipolar disorder clinical programs. The decision followed observations of elevated neuropsychiatric adverse event rates, encompassing confusion, drowsiness, coordination problems, and isolated psychosis cases.
Xenon Pharmaceuticals Inc., XENE
In Friday’s premarket session, XENE plummeted 25% to reach $42.84. Should these declines persist through regular trading, it would represent the stock’s steepest single-session loss since March 2017, when shares collapsed 53%āstill the company’s record decline. The price would also hit its lowest level in half a year.
According to Xenon, these safety signals aligned with azetukalner’s established risk profile but hadn’t emerged during earlier-stage studies. Management characterized the enrollment suspension as a precautionary step likely to be temporary.
The biotech firm indicated plans to assess alternative dosing strategies, potentially incorporating gradual dose escalation or reduced maximum doses, aimed at enhancing patient tolerance prior to restarting enrollment.
Analyst Community Divided
David Hoang from Deutsche Bank cut his rating on XENE from Buy to Hold while dramatically reducing his target price from $90 to $46. His rationale centered on concerns that this development undermines azetukalner’s competitive positioning in the focal epilepsy market.
Conversely, Wells Fargo’s Benjamin Burnett maintained his Overweight stance. His analysis concluded that the psychiatric trial suspension carries no implications for the focal onset seizures program.
Needham analysts lowered their target from $78 to $60 while preserving their Buy recommendation. The firm completely eliminated revenue assumptions for depression and bipolar disorder indications from their azetukalner financial projections.
Needham highlighted the uncertainty surrounding whether adjusted dosing regimens could adequately mitigate neuropsychiatric risks without compromising therapeutic efficacy.
Clinical Program Updates and Next Steps
Prior to the enrollment halt, the X-NOVA2 phase 3 depression trial had recruited 80% of its planned 450-participant cohort. Topline data readout remains scheduled for Q1 2027.
Management stated that decisions regarding resumption of the depression and bipolar programs will follow after reviewing X-NOVA2 results.
H.C. Wainwright reaffirmed its Buy rating with a $74 target, emphasizing that FDA reviewers raised no drug exposure concerns during pre-NDA discussions about the epilepsy application.
Xenon maintains a net cash position on its balance sheet. According to InvestingPro’s valuation analysis, fair value sits at $52.77, indicating the stock traded above fair value even prior to Friday’s selloff.
Wall Street consensus doesn’t anticipate profitability for Xenon in the current year. Prior to Thursday’s announcement, shares had climbed 52% over the trailing twelve months.
Needham’s updated $60 target price exclusively incorporates epilepsy market potential for azetukalner, completely excluding any contribution from psychiatric applications.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
